Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY)
FB Riley Healthcare Conference( Sept 4th)
Marriot East Side. 525 Lexington Avenue, New York, NY10017. Morgan Room.
2:55 pm: “A beginner’s guide to T-Cell Cancer Therapy” (Panel)
5:15 pm: “The Commercial Pain of CAR-T Cell Therapies Will Limit Their Scope (Panel) HC Wainwright Healthcare Conference( Sept 5th)
The St. Regis New York. 2 E 55th Street,
New York, NY10022. Library (2nd floor).
3:00 pm: Corporate Overview (Presentation)
A copy of the corporate presentation will be made available on the Sorrento investor relations website (www.sorrentotherapeutics.com)
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its’ extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Sephrevir®”).
Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin (“RTX”) and ZTlido™. Resiniferatoxin is completing a phase IB trial in terminal cancer patients. ZTlido was approved by US FDA on 02/28/18.
For more information visit www.sorrentotherapeutics.com
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to
Media and Investor Relations
Sorrento® and the Sorrento logo are registered trademarks of
ZTlido™ and G-MAB™ are trademarks owned by
Seprehvir®, is a registered trademark of Virttu Biologics Limited, a wholly-owned subsidiary of
All other trademarks are the property of their respective owners.
Source: Sorrento Therapeutics, Inc.